&w=3840&q=100)
Asian Paints shares rise 3% after large deal in pre-open; all details here
Asian Paints share price gained 2.5 per cent in trade on Thursday, June 12, 2025, logging an intraday high at ₹2,263.95 per share on BSE. The buying on the counter came after a large deal took place in the pre-opening session.
At 9:57 AM, Asian Paints shares were trading 2.06 per cent lower at ₹2,254 per share on the BSE. In comparison, the BSE Sensex was down 0.12 per cent at 82,412.64. The company's market capitalisation stood at ₹2,16,203.18 crore. Its 52-week high was at ₹3,394 per share and 52-week low was at ₹2,125 per share.
Asian Paints block deal details
According to data available on Bloomberg, 35 million shares changed hands in a single block deal on NSE in the market pre-opening session. This accounted for 3.65 per cent of equity. Block changed hands at ₹2,201 per share against last close of ₹2,208.8 per share. Buyers and sellers of the deals were not disclosed.
As of quarter ending March 2025, India's mutual funds have a 5.67 per cent stake in Asian Paints at the end of the March quarter, with ICICI Prudential Mutual Fund holding at 1.24 per cent and SBI Mutual Fund at 1.51 per cent.
Besides, Life Insurance Corporation of India holds 8.29 per cent stake in the company.
The complaint was filed by Aditya Birla group in November last year, alleging that Asian Paints, which is the market leader with 53 per cent market share, had indulged in anti-competitive conduct and exclusionary practices.
The allegations included restricting dealers from doing business with Grasim's Birla Opus. Grasim is a flagship company of the Aditya Birla group. It was also alleged that Asian Paints had put pressure on raw material suppliers to deny (supplies) or price-discriminate against Birla Opus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
8 hours ago
- Mint
Anant Ambani to get THIS amount as salary as Executive Director of Reliance — Check details
Mukesh Ambani-run oil marketing major Reliance Industries appointed Anant Ambani as one of the company's Full-Time directors. As a board member, Anant Ambani will be paid ₹ 10 crore to ₹ 20 crore, according to an exchange filing on Sunday, 29 June 2025. The filing data shows that Ambani's annual salary will comprise the main salary component, along with perquisites and allowances. The company also highlighted that the annual increments will be determined by the HRNR Committee at Reliance. 'Salary, Perquisites and Allowances shall be in the range of ₹ 10 crore to ₹ 20 crore per annum. Annual increments shall be as determined by the HRNR Committee,' said Reliance in its BSE filing. The perquisites and allowances will include accommodation cost or house rent allowance, gas, electricity, water, among other provisions as per the Income Tax Act of 1961. Reliance's contribution to Anant Ambani's provident fund, superannuation or annuity fund, gratuity payable and encashment of leave will be carried out as per the rules of the firm. However, these extra benefits will be provided in addition to Anant Ambani's salary of ₹ 10-20 crore. On top of the take-home salary, Anant Ambani will also receive an extra payment based on the net profits of the company. The company will also grant reimbursements on expenses incurred by Anant Ambani, his wife and attendant's travelling, boarding and lodging, according to the company's disclosure. According to the official filing data, the board of directors held their meeting on 15 April 2025, and approved the appointment of Anant Ambani a the Whole-time Director, designated as an Executive Director for the next five years effective 1 May 2025. His salary component also comes along with security and medical reimbursement as per Reliance's policy for senior managerial executives. Anant Ambani has been appointed as the Whole-Time director at Reliance along with his Executive Director position for the next five years, effective 1 May 2025. 'The Board of Directors of the Company, at its meeting held on 25 April 2025, subject to the approval of members, appointed Shri Anant M. Ambani (DIN: 07945702) as a Whole-time Director, designated as an Executive Director, for a period of 5 (five) years, with effect from 1 May 2025,' said the company in the exchange filing.
Mint
8 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee
Mint
8 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
